Novavax Advances Development of Novel COVID-19 Vaccine
- Vaccine candidate derived from coronavirus spike (S) protein
- Matrix-M™ adjuvant expected to boost immune responses
- Phase 1 clinical trial planned for late spring
“Our previous experience working with other coronaviruses, including both MERS and SARS, allowed us to mobilize quickly against COVID-19 and successfully complete the critical preliminary steps to engineer viable vaccine candidates,” said
A new strain of coronavirus first appeared in late 2019 in
Novavax’ patented saponin-based Matrix-M adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune responses.
Statements herein relating to the future of
Source: Novavax, Inc.